Sandoz: strategic roadmap confirmed
(CercleFinance.com) - On Tuesday, Sandoz gave an update on its strategy during a presentation at J.
P. Morgan's annual healthcare conference, currently being held in San Francisco.
Novartis' former subsidiary, which became independent in October 2023, underlined the soundness of its positioning, pointing out that generics and biosimilars today account for 80% of drug consumption, for only 30% of their total costs.
With an aging population, the rise of chronic diseases and the expiry of numerous patents, Sandoz expects its market to grow by an average of 7% p.a. over the next 10 years.
Already the leader in the European market, which now accounts for half of its sales, the Swiss laboratory is aiming to become number one in biosimilars in the US, with three launches planned across the Atlantic this year.
This year, it plans to market biosimilar versions of Pyzchiva (Crohn's disease and UC) and Tyruko (multiple sclerosis) on the US market, Wyost (bone cancer) and Jubbonti (osteoporosis) in the US and Europe, and Afqlir (retinal diseases) on the Old Continent.
Its pipeline currently comprises 28 compounds.
With the emergence of GLP-1 anti-obesity treatments, Sandoz also says it is working with its partner Pharmathen to commercialize weight-loss drugs in the US, Europe and other markets.
Following these announcements, Sandoz shares rose by 0.7% on Tuesday on the Zurich Stock Exchange.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
P. Morgan's annual healthcare conference, currently being held in San Francisco.
Novartis' former subsidiary, which became independent in October 2023, underlined the soundness of its positioning, pointing out that generics and biosimilars today account for 80% of drug consumption, for only 30% of their total costs.
With an aging population, the rise of chronic diseases and the expiry of numerous patents, Sandoz expects its market to grow by an average of 7% p.a. over the next 10 years.
Already the leader in the European market, which now accounts for half of its sales, the Swiss laboratory is aiming to become number one in biosimilars in the US, with three launches planned across the Atlantic this year.
This year, it plans to market biosimilar versions of Pyzchiva (Crohn's disease and UC) and Tyruko (multiple sclerosis) on the US market, Wyost (bone cancer) and Jubbonti (osteoporosis) in the US and Europe, and Afqlir (retinal diseases) on the Old Continent.
Its pipeline currently comprises 28 compounds.
With the emergence of GLP-1 anti-obesity treatments, Sandoz also says it is working with its partner Pharmathen to commercialize weight-loss drugs in the US, Europe and other markets.
Following these announcements, Sandoz shares rose by 0.7% on Tuesday on the Zurich Stock Exchange.
Copyright (c) 2025 CercleFinance.com. All rights reserved.